© The Financial Times Ltd 2016 FT and 'Financial Times' are trademarks of The Financial Times Ltd.
As of Feb 06, 2016, the consensus forecast amongst 23 polled investment analysts covering Gilead Sciences, Inc. advises that the company will outperform the market. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Oct 21, 2009. The previous consensus forecast advised investors to purchase equity in Gilead Sciences, Inc..
|Last year||3 months ago||2 months ago||4 weeks ago||Latest|
The 20 analysts offering 12 month price targets for Gilead Sciences, Inc. have a median target of 120.00, with a high estimate of 137.00 and a low estimate of 91.00. The median estimate represents a 40.75% increase from the last price of 85.26. View Full Financials
In 2015, Gilead Sciences Inc reported a dividend of 1.29 USD. The 9 analysts covering the company expect dividends of 1.87 USD for the upcoming fiscal year, an increase of 45.12%. View Full Financials
|Div growth (TTM)||--|
On Feb 02, 2016, Gilead Sciences, Inc. reported 4th quarter 2015 earnings of 3.32 per share. This result exceeded the 3.00 consensus of the 19 analysts covering the company and exceeded last year's 4th quarter results by 36.63%.
The next earnings announcement is expected on Apr 28, 2016. View Full Interim Financials
|Average growth rate||+8.36 %|
Gilead Sciences, Inc. reported annual 2015 earnings of 12.61 per share on Feb 02, 2016. View Full Annual Financials
|Average growth rate||+89.52 %|
Gilead Sciences Inc. had 4th quarter 2015 revenues of 8.51bn. This bettered the 8.13bn consensus of the 18 analysts covering the company. This was 16.30% above the prior year's 4th quarter results. View Full Interim Financials
|Average growth rate||+3.89 %|
Gilead Sciences Inc. had revenues for the full year 2015 of 32.64bn. This was 31.13% above the prior year's results. View Full Annual Financials
|Average growth rate||+46.12 %|